Atlas Trials

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Clinical trial NCT04342910 · RECRUITING

Trial details

NCT number
NCT04342910
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2020-09-21
Primary completion
2026-04-01
Enrollment
550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.